Lupin Limited delivered a strong start to fiscal year 2027, reporting consolidated revenue of ₹82.77B for Q1 FY27, surpassing analyst estimates of ₹79B and marking a significant year-on-year increase from ₹61.6B. Consolidated sales stood at ₹82,172 Mn, reflecting a 33.3% year-on-year rise. Profit after tax (PAT), adjusted for non-controlling interests, rose 16.1% to ₹14,150 Mn, ahead of the analyst estimate of ₹13.77B. The growth was underpinned by double-digit expansions across key geographies, particularly the United States, which contributed 42% of total revenue, and emerging markets that saw sales more than double in certain segments. This performance highlights the company's ability to drive volume growth while maintaining operational efficiency despite global regulatory complexities.

The Board of Directors approved these unaudited results at a meeting held on August 06, 2026, pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The financial statements were prepared in accordance with IND-AS standards. Lupin's investor presentation, released on August 07, 2026, provided further granularity on segmental performance and strategic initiatives, including significant advancements in its complex generics and biosimilars pipeline.

Financial Highlights

Lupin's top-line growth was accompanied by a substantial improvement in operating margins. EBITDA came in at ₹24.5B, beating the analyst estimate of ₹22.23B and rising sharply from ₹17.3B in the year-ago period. EBITDA margin stood at 29.59% compared to 27.56% in Q1 FY26, exceeding the estimate of 28.10%. On an adjusted basis excluding forex and other income, EBITDA increased by 50.1% to ₹24,635 Mn, with the EBITDA margin expanding to 30.0% from 26.6% in the corresponding period last year. Gross profit rose sharply by 39.5% to ₹61,280 Mn, reflecting a gross margin of 74.6%, up from 71.3% in Q1 FY26. This margin expansion was achieved despite higher operational investments, including personnel costs which increased by 27.7% to ₹13,830 Mn and manufacturing expenses that rose 32.1% to ₹23,412 Mn.

Profit before tax climbed significantly, driving the overall profitability improvement. However, tax expenses increased to ₹6,004 Mn compared to ₹1,940 Mn in Q1 FY26, impacting the net profit growth rate relative to pre-tax earnings. Other income declined by 42.9% to ₹597 Mn, while forex losses stood at ₹139 Mn, a reversal from the ₹859 Mn gain recorded in Q1 FY26. Research and development expenditure rose to ₹6,077 Mn, representing 7.4% of sales, supporting the company's focus on complex generics and biosimilars.

Regional Performance

The U.S. market remained the largest contributor, with sales jumping 42.9% to ₹34,348 Mn (including IP income). In dollar terms, U.S. sales reached $366 Mn, up 30% year-on-year but down 1% quarter-on-quarter due to mid-single-digit price declines from increased competition in select products like Mirabegron. Emerging markets showed the highest growth rate at 51.7%, reaching ₹9,897 Mn, followed by Other Developed Markets at 48.3% growth to ₹11,494 Mn. India sales grew 13.9% to ₹23,796 Mn, outperforming the industry prescription market (IPM) growth of ~13.5%. The India Rx business grew by 15.1%, driven by strong performances in Anti-Diabetes (up 31.8%) and Cardiology segments.

Strategic Developments and Pipeline

Lupin continued to strengthen its portfolio through new approvals and launches. The company secured six new ANDA approvals from the U.S. FDA during the quarter and launched three new products, bringing its total generic portfolio in the U.S. to 149 products. Key launches included Azilsartan Medoxomil in the U.S. and Ranibizumab biosimilar approval. In India, seven new brands were launched, with plans for over 20 more in FY27. The company also received EMA approval to extend NaMuscla® for children aged 6–17 years and secured China approval for Oseltamivir Phosphate oral suspension, marking its first entry into that market.

What the Numbers Show

A notable divergence exists between the growth in EBITDA (50.1%) and Net Income (16.1%). This gap is largely attributable to a sharp rise in tax provisions, which more than tripled year-on-year, alongside a decline in other income. Additionally, while revenue growth was broad-based, the U.S. segment continues to dominate at 42% of total sales, highlighting a persistent concentration risk despite strong gains in emerging markets. The company's net debt position improved to a net cash balance, with net debt to equity standing at (0.12), providing a strong liquidity buffer for future R&D investments and potential M&A activities in the specialty and complex generics space.

Lupin Limited reported a 27% year-on-year increase in standalone net profit after tax (PAT) to ₹27,146 million for the quarter ended June 30, 2026, driven by strong revenue growth across its core pharmaceutical business. The company’s consolidated revenue from operations surged 32% to ₹82,769 million, while consolidated PAT rose 16% to ₹14,170 million. These results reflect sustained momentum in the US generics market and effective cost management, positioning the firm for continued expansion in FY26.

The Board of Directors, chaired by Managing Director Nilesh D. Gupta, approved the unaudited standalone and consolidated financial results at a meeting held on August 06, 2026. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, Deloitte Haskins & Sells Chartered Accountants LLP, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

Standalone sales/income from operations jumped 27% to ₹71,125 million from ₹56,054 million in Q1FY25. Total revenue from operations reached ₹71,719 million. On a consolidated basis, total income stood at ₹84,072 million, compared to ₹63,474 million in the corresponding quarter last year. The Pharmaceuticals segment contributed ₹82,344 million to consolidated revenue, accounting for the vast majority of the group’s top-line growth.

The standalone basic earnings per share (EPS) increased to ₹59.37 from ₹46.60 in the previous year’s quarter. Consolidated basic EPS rose to ₹30.95 from ₹26.70. Other income for the standalone entity was ₹1,025 million, while consolidated other income stood at ₹1,303 million.

Key Developments and Segment Analysis

The Pharmaceuticals segment generated a result before tax and exceptional items of ₹20,606 million in the consolidated books, up significantly from ₹14,578 million in Q1FY25. This growth underscores the segment’s dominance in driving profitability. The 'Others' segment reported a loss of ₹432 million, consistent with its historical pattern of lower margins.

During the quarter, Lupin concluded the acquisition of wholly-owned subsidiary VISUfarma B.V., Netherlands, through Nanomi B.V. on April 01, 2026. The total consideration was ₹20,903 million (Euro 192.8 million). The fair value of intangibles acquired was ₹15,971 million, with goodwill provisionally accounted at ₹6,030 million based on an independent valuer’s report. Additionally, 53,425 equity shares were allotted upon the exercise of vested stock options under the Lupin Employees Stock Option Plans, increasing paid-up capital by ₹0.1 million and securities premium by ₹76.9 million.

What the Numbers Show

A notable divergence exists between standalone and consolidated profitability metrics. While standalone PAT grew by 27%, consolidated PAT growth was more modest at 16%. This gap is primarily attributable to higher tax expenses and integration costs associated with recent acquisitions, including VISUfarma. Furthermore, the group recognized an impairment charge of ₹879 million during the quarter related to certain capital work-in-progress and intangible assets under development. Despite these headwinds, the core pharmaceutical business demonstrated resilience, with revenue growth outpacing expense inflation, indicating strong operational leverage in key markets.